U.S., Feb. 3 -- ClinicalTrials.gov registry received information related to the study (NCT07381543) titled 'Adebrelimab Maintenance Therapy for LS-SCLC Post Induction Chemo-Adebrelimab Plus CRT or CRT Alone' on Jan. 18.
Brief Summary: Observation and Evaluation of the Efficacy and Safety of Adalimumab Combined with Chemotherapy Followed by Radiotherapy or Radiotherapy Alone as First-Line Treatment for Limited-Stage Small Cell Lung Cancer
Study Start Date: March, 2026
Study Type: INTERVENTIONAL
Condition:
Localized Small Cell Lung Cancer
Intervention:
DRUG: Arm A
Induction Phase First, adebrelimab (1200 mg, IV, D1, Q3W) is administered in combination with EC/EP chemotherapy for two cycles of induction therapy. This was followed by tw...